148 related articles for article (PubMed ID: 8519494)
1. Morphofunctional characterization of lymphokine activated killer (LAK) cells in vitro.
Nano R; Capelli E; Gerzeli G
Boll Soc Ital Biol Sper; 1995; 71(7-8):181-7. PubMed ID: 8519494
[TBL] [Abstract][Full Text] [Related]
2. The role of lymphotoxin in the IL-2-driven differentiation of human lymphokine-activated T-killer (T-LAK) cells in vitro.
Abe Y; Van Eden M; Gatanaga M; Wang FI; Brightbill HD; Granger GA; Gatanaga T
Lymphokine Cytokine Res; 1993 Oct; 12(5):279-83. PubMed ID: 8260536
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of cytolytic activity and cell surface phenotypes of lymphokine activated killer cells stimulated with R-IL 2 and an anti-CD 3 antibody].
Kikuchi T; Sakai H; Nakamura N; Watanabe M; Ohno T
No To Shinkei; 1990 Jun; 42(6):575-80. PubMed ID: 2119634
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
5. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
6. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity in lectin-binding characteristics of human lymphokine-activated killer cells.
Maruyama T; Imai Y; Harada K; Okada T; Takano M; Ikeda Y; Toda G; Oka H; Osawa T
J Biol Response Mod; 1990 Aug; 9(4):378-86. PubMed ID: 2395003
[TBL] [Abstract][Full Text] [Related]
8. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
Harthun NL; Weaver AM; Brinckerhoff LH; Deacon DH; Gonias SL; Slingluff CL
J Immunother; 1998 Mar; 21(2):85-94. PubMed ID: 9551359
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear adherent cells culture.
Eisenthal A; Barbarsteyn E; Gitstein G; Lifschitz-Mercer B
Cancer Invest; 2006 Feb; 24(1):28-34. PubMed ID: 16466989
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2 killer cells: in vitro evaluation of combination with prothymosin alpha.
López-Rodríguez JL; Cordero OJ; Sarandeses C; Viñuela J; Nogueira M
Lymphokine Cytokine Res; 1994 Jun; 13(3):175-82. PubMed ID: 7948426
[TBL] [Abstract][Full Text] [Related]
11. In vivo activation of LAK cells during systemic IL-2 therapy.
Lang P; Vitté-Mony I; Farace F; Stancou R; Triebel F; Escudier B; Hercend T; Bertoglio J
Eur Cytokine Netw; 1990; 1(3):185-8. PubMed ID: 2129800
[No Abstract] [Full Text] [Related]
12. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients.
Provinciali M; Di Stefano G; Stronati S; Fabris N
Cytokine; 1998 Feb; 10(2):132-9. PubMed ID: 9512903
[TBL] [Abstract][Full Text] [Related]
13. Phenotypical study of human lymphokine-activated killer (LAK) cells.
Barral AM; García CA
Neoplasma; 1989; 36(5):583-8. PubMed ID: 2682296
[TBL] [Abstract][Full Text] [Related]
14. Augmentation of lymphokine-activated killer cell activity by lentinan.
Tani M; Tanimura H; Yamaue H; Tsunoda T; Iwahashi M; Noguchi K; Tamai M; Hotta T; Mizobata S
Anticancer Res; 1993; 13(5C):1773-6. PubMed ID: 8267381
[TBL] [Abstract][Full Text] [Related]
15. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
16. The effects of recombinant human IL-2 in miniature swine.
Nakajima K; Smith CV; Mixon A; Rosengard BR; Guzzetta PC; Spitzer TR; Eckhaus MA; Sachs DH
Transplant Proc; 1991 Feb; 23(1 Pt 1):248-50. PubMed ID: 1990524
[No Abstract] [Full Text] [Related]
17. Evaluation of lymphokine-activated killer cell development in young and old healthy humans.
Provinciali M; Di Stefano G; Fabris N
Nat Immun; 1995; 14(3):134-44. PubMed ID: 8832897
[TBL] [Abstract][Full Text] [Related]
18. Lymphokine-activated killer cells can kill target cells not only by early killing but also by late killing, and the late killing level against autotumor cell line.
Komatsu F; Ishiguro K
Oncol Res; 2003; 13(4):235-41. PubMed ID: 12659424
[TBL] [Abstract][Full Text] [Related]
19. Characterization of lymphokine-activated killing by human peripheral blood mononuclear cells stimulated with interleukin 2 (IL-2) analogs specific for the intermediate affinity IL-2 receptor.
Heaton KM; Ju G; Morris DK; Delisio K; Bailon P; Grimm EA
Cell Immunol; 1993 Mar; 147(1):167-79. PubMed ID: 8462109
[TBL] [Abstract][Full Text] [Related]
20. IL-2-activated cord blood mononuclear cells.
Derzic S; Slone V; Sender L
Cytotherapy; 2005; 7(5):408-16. PubMed ID: 16236630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
